
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Review |
1 Epidemiology and Biostatistics Unit, Aviano Cancer Center, Aviano, Italy and 2 International Agency for Research on Cancer, Lyon, France
Requests for reprints: Luigino Dal Maso, Epidemiology and Biostatistics Unit, Centro di Riferimento Oncologico, IRCCS, Via Pedemontana occidentale 12, 33081 Aviano (PN), Italy. Phone: 39-0434-659354; Fax: 39-0434-659222. E-mail: epidemiology{at}cro.it
The present meta-analysis was conducted to evaluate the strength and the consistency of the association between hepatitis C virus (HCV) infection and nonHodgkin lymphoma (NHL) and other lymphoid neoplasms. Only studies with
100 cases which were also adjusted for sex and age were included. Fifteen case-control studies and three prospective studies contributed to present analysis, nine of which had not been included in previous meta-analyses. We calculated the pooled relative risks (RR) with corresponding 95% confidence intervals (95% CI), as a weighted average of the estimated RRs by random-effect models. The pooled RR of all NHL among HCV-positive individuals was 2.5 (95% CI, 2.1-3.0), but substantial heterogeneity was found between studies and by study design. Pooled RRs were 2.5 (95% CI, 2.1-3.1) in case-control studies and 2.0 (95% CI, 1.8-2.2) in cohort ones. The strongest source of heterogeneity seemed to be the prevalence of HCV among NHL-free study subjects (RR for NHL among HCV-positive individuals 3.0 and 1.9, respectively, for
5% and <5% HCV prevalence). RRs were consistently increased for all major B-NHL subtypes, T-NHL, and primary sites of NHL presentation. Thus, previous suggestions that the RRs for HCV differed by NHL subtype were not confirmed in our meta-analysis. Associations weaker than with NHL were found between HCV infection and Hodgkin's lymphoma (RR, 1.5; 95% CI, 1.0-2.1) and multiple myeloma (RR, 1.6; 95% CI, 0.7-3.6), but they were based on much fewer studies than NHL. The etiologic fraction of NHL attributable to HCV varies greatly by country, and may be upward of 10% in areas where HCV prevalence is high. (Cancer Epidemiol Biomarkers Prev 2006;15(11):207885)
This article has been cited by other articles:
![]() |
L. A. Anderson, R. Pfeiffer, J. L. Warren, O. Landgren, S. Gadalla, S. I. Berndt, W. Ricker, R. Parsons, W. Wheeler, and E. A. Engels Hematopoietic Malignancies Associated with Viral and Alcoholic Hepatitis Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3069 - 3075. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Hassan, D. Li, A. S. El-Deeb, R. A. Wolff, M. L. Bondy, M. Davila, and J. L. Abbruzzese Association Between Hepatitis B Virus and Pancreatic Cancer J. Clin. Oncol., October 1, 2008; 26(28): 4557 - 4562. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Schollkopf, M. Melbye, L. Munksgaard, K. E. Smedby, K. Rostgaard, B. Glimelius, E. T. Chang, G. Roos, M. Hansen, H.-O. Adami, et al. Borrelia infection and risk of non-Hodgkin lymphoma Blood, June 15, 2008; 111(12): 5524 - 5529. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Brown, G. Gridley, D. Check, and O. Landgren Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders Blood, April 1, 2008; 111(7): 3388 - 3394. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Morton, O. Landgren, N. Chatterjee, D. Castenson, R. Parsons, R. N. Hoover, and E. A. Engels Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients Blood, December 15, 2007; 110(13): 4599 - 4605. [Abstract] [Full Text] [PDF] |
||||
![]() |
D S Viswanatha and A Dogan Hepatitis C virus and lymphoma J. Clin. Pathol., December 1, 2007; 60(12): 1378 - 1383. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Giordano, L. Henderson, O. Landgren, E. Y. Chiao, J. R. Kramer, H. El-Serag, and E. A. Engels Risk of Non-Hodgkin Lymphoma and Lymphoproliferative Precursor Diseases in US Veterans With Hepatitis C Virus JAMA, May 9, 2007; 297(18): 2010 - 2017. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |